Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function

Area of Science:

• Infectious Diseases
• Pharmacology
• Immunology

Background:

• Invasive fungal disease treatment failure is common, often due to a lack of understanding of antifungal drug mechanisms within the host.
• Voriconazole exhibits potent in vitro antifungal activity, but its in vivo efficacy and precise mechanism remain incompletely understood.

Purpose of the Study:

• To investigate the in vivo efficacy and mechanism of the antifungal drug voriconazole against Aspergillus fumigatus infection.
• To elucidate the role of host immune cells in mediating voriconazole's therapeutic effect using a live vertebrate model.

Main Methods:

• Utilized a transparent larval zebrafish model of Aspergillus fumigatus infection for real-time in vivo imaging.
• Observed the interaction between voriconazole, Aspergillus fumigatus, and host innate immune cells, particularly macrophages, over a multiday course.

Main Results:

• Voriconazole's protective effect against Aspergillus fumigatus infection in vivo is dependent on the presence of host macrophages.
• In the zebrafish model, voriconazole did not inhibit fungal spore germination but rather targeted post-germination hyphae.
• Macrophages were observed to slow initial fungal growth, creating a window for voriconazole to effectively eliminate fungal hyphae.

Conclusions:

• Host innate immunity, specifically macrophages, is crucial for the in vivo efficacy of voriconazole.
• Voriconazole's mechanism of action in vivo involves a synergistic interaction with the host immune response, rather than direct inhibition of fungal germination.
• These findings highlight the importance of considering host-pathogen-drug interactions for optimizing antifungal therapies.